Acute pancreatitis (AP) leads to endothelial cells damage, increased vascular permeability, adhesion, rolling and transmigration of leukocytes to the pancreatic tissue and coagulation disruption. The aim of the study was to determine whether administration of rivaroxaban, a factor Xa inhibitor in the coagulation pathway, alleviates the course of cerulein-induced AP and accelerates the pancreatic recovery. In the first part of the study, we administered 5, 20 and 100 mg/kg/dose of rivaroxaban before AP induction with cerulein, in the second part, the drug was administered daily after AP onset. We weighed the pancreas and conducted histopathological examination 6 h after the last dose of cerulein and on days 2, 3, 5, 7 and 10 of the experiment. We measured INR levels, pancreatic enzymes activity, pancreatic blood flow, D-dimer concentration and inflammatory markers such as Interleukin 1β (IL-1β), myeloperoxidase (MPO), superoxide dismutase (SOD) and malondialdehyde (MDA). Rivaroxaban at the dose of 5 and 20 mg/kg reduced the pancreatic damage, such as edema, vacuolization, and the number of hemorrhagic foci. These effects were accompanied by a decrease in the activity of amylase, lipase and the concentration of IL-1β and D-dimers. In addition, an improvement in pancreatic blood flow was observed, and a lower concentration of MDA and a higher SOD in the first days from the AP on ; set were recorded. Rivaroxaban at 100 mg/kg resulted in increased pancreatic damage and worse AP scores. Early administration of rivaroxaban had a protective effect on the pancreas and treatment with the drug reduced AP severity.
Rada Dyscypliny Nauki medyczne
Ceranowicz, Piotr ; Macyk, Wojciech
6 lut 2024
6 lut 2024
6
0
http://dl.cm-uj.krakow.pl:8080/publication/5017
Nazwa wydania | Data |
---|---|
ZB-138270 | 6 lut 2024 |
Maraj, Małgorzata
Cieszkowski, Jakub
Dembiński, Marcin
Góralczyk, Tadeusz
Konarska-Bajda, Katarzyna
Bukowczan, Jakub
Kopytek, Magdalena
Chmiel, Izabela